Meta-analysis of 14 RCTs (6,412 patients with CKD): endothelin receptor antagonists reduced ESKD risk vs control (RR 0.76), reduced proteinuria and lowered BP, without more oedema or heart failure, but hypotension was more frequent (RR 1.92).
Meta-analysisn = 6,412
Shi et al. Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD